Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Badid, C.
Right arrow Articles by Laville, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Badid, C.
Right arrow Articles by Laville, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 1752-1756
© 2001 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Mycophenolate mofetil: implications for the treatment of glomerular disease

Chérif Badid1, Alexis Desmouliere2 and Maurice Laville1,

1 Département de Néphrologie et EA645, Université Claude Bernard, Hopital Edouard Herriot, Lyon and 2 GREF, Université Victor Segalen Bordeaux 2, Bordeaux, France

Keywords: inflammatory glomerular disease; mycophenolate mofetil

Introduction

Mycophenolate mofetil (MMF) is a specific inhibitor of inosine monophosphate dehydrogenase, which is involved in de novo purine synthesis. MMF is a suppressor of both T and B cell lymphocyte proliferation [1,2] and has been used successfully for the prevention of acute and chronic rejection of renal allografts [3,4]. MMF is more effective than azathioprine in preventing acute rejection. Interestingly, although MMF has been introduced as an immunosuppressive drug, it has also effects on non-immune cells. In particular it has an antiproliferative action on vascular smooth muscle cells [5,6] and this may be responsible, at least in part, for the beneficial effect of MMF on chronic graft dysfunction [7].

Only limited information is available with respect to the use of MMF for the treatment of autoimmune diseases. There are experimental studies documenting that MMF inhibits the . . . [Full Text of this Article]

Mechanisms of action and pharmacokinetics

Action of mycophenolate on specific cell functions

Selective inhibition of lymphocyte functions
Deoxyguanosine nucleotide depletion
Effects on non-immune cells
Mycophenolate mofetil and experimental models of glomerular disease

Mycophenolate mofetil in human glomerular disease

MMF and recurrent glomerulonephritis in allografts
Mycophenolate mofetil and primary glomerular diseases
Mycophenolate mofetil and lupus nephritis
Mycophenolate mofetil and vasculitis
Nephrotic syndrome
IgA nephropathy
Conclusions

Acknowledgments

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
M. Polenakovic, L. Grcevska, and S. Dzikova
Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy
Nephrol. Dial. Transplant., June 1, 2003; 18(6): 1233 - 1234.
[Full Text] [PDF]